Teva replaces Ranbaxy in making Nexium copy; Novartis selling closed site to university;

> Ranbaxy Laboratories' ongoing quality issues have led the FDA to grant Teva ($TEVA) approval to make a copy of AstraZeneca's ($AZN) blockbuster Nexium. Story

> France is taking action against Chinese antibiotics maker North China Pharmaceutical Group Semisyntech after finding documentation issues in its quality control department. Find the report here

> Solvay announced it will build a new manufacturing and filling facility in the Netherlands to produce hydrogen peroxide to meet demand from the pharma industry. Announcement

> Novartis ($NVS) says it is in exclusive talks with The University of Brighton to sell its former R&D site in Horsham, West Sussex, which was closed last year. Story

> India contract manufacturer Neuland Laboratories says one of its two key manufacturing sites in India has again successfully passed an FDA audit. Release

> Australia's Therapeutic Goods Administration (TGA) has updated guidance, requiring the last manufacturer in the supply chain of a drug to be responsible for certifying the quality before the products are released onto the Australian market. Report

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.